Skip to main content
Premium Trial:

Request an Annual Quote

Caprion Taps McGill University to Help Expand Its Proteomics Effort

NEW YORK, Feb. 27 - Caprion Pharmaceuticals has asked neighboring McGill University to help expand its proteomics research, the company said on Wednesday.

Terms of this open-ended agreement call for Caprion to give McGill roughly C$1 million for certain proteomics research performed by John Bergeron, chair of the anatomy and cell biology department at McGill who also is Caprion's chief scientific officer for proteomics. 

 

Caprion said it will have access to certain IP to any "technical innovations" developed under the collaboration, along with exclusive rights to license any proteomic technologies that may develop.

 

"Partnering with Caprion provides significant long-term funding that is not always available to our academic researchers," Pierre Bélanger, vice principal for research at McGill, said in a statement. Abe Fuks, dean of medicine at the school, added that the alliance "supports fundamental research at McGill while helping train the next generation of graduates to better meet industrial needs."

 

Caprion and McGill are both based in Montreal.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.